Guardant Health, Inc. (NASDAQ:GH) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 1.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,950,230 shares of the company's stock after purchasing an additional 146,902 shares during the quarter. Vanguard Group Inc. owned about 9.28% of Guardant Health worth $324,565,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Capital International Investors boosted its holdings in Guardant Health by 71.0% in the first quarter. Capital International Investors now owns 5,081,624 shares of the company's stock valued at $336,607,000 after acquiring an additional 2,110,240 shares during the last quarter. Alliancebernstein L.P. raised its position in Guardant Health by 35.2% in the second quarter. Alliancebernstein L.P. now owns 4,463,669 shares of the company's stock valued at $159,799,000 after purchasing an additional 1,161,901 shares during the period. Eventide Asset Management LLC raised its position in Guardant Health by 113.8% in the second quarter. Eventide Asset Management LLC now owns 4,008,602 shares of the company's stock valued at $143,508,000 after purchasing an additional 2,133,582 shares during the period. Temasek Holdings Private Ltd increased its position in shares of Guardant Health by 8.2% during the second quarter. Temasek Holdings Private Ltd now owns 3,963,872 shares of the company's stock worth $141,907,000 after acquiring an additional 299,510 shares during the last quarter. Finally, Clearbridge Investments LLC increased its position in shares of Guardant Health by 8.0% during the first quarter. Clearbridge Investments LLC now owns 3,354,024 shares of the company's stock worth $222,171,000 after acquiring an additional 247,486 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Guggenheim assumed coverage on Guardant Health in a research note on Thursday, December 14th. They issued a "neutral" rating for the company. Piper Sandler reduced their target price on Guardant Health from $40.00 to $30.00 and set an "overweight" rating for the company in a report on Monday, February 26th. The Goldman Sachs Group dropped their price target on shares of Guardant Health from $43.00 to $37.00 and set a "buy" rating on the stock in a research note on Monday, January 29th. Wolfe Research initiated coverage on shares of Guardant Health in a research report on Wednesday, December 13th. They set a "peer perform" rating on the stock. Finally, JPMorgan Chase & Co. lowered their target price on shares of Guardant Health from $60.00 to $45.00 and set an "overweight" rating on the stock in a research report on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $41.30.

Guardant Health Stock Up 14.9 %

NASDAQ:GH traded up $2.67 during trading hours on Thursday, reaching $20.63. The company had a trading volume of 5,568,511 shares, compared to its average volume of 1,771,209. The company has a quick ratio of 6.24, a current ratio of 6.54 and a debt-to-equity ratio of 7.18. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -4.82 and a beta of 0.87. The business's 50-day simple moving average is $20.56 and its two-hundred day simple moving average is $24.44. Guardant Health, Inc. has a twelve month low of $16.92 and a twelve month high of $41.06.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.93) by ($0.65). Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. The firm had revenue of $155.05 million for the quarter, compared to the consensus estimate of $151.71 million. On average, equities analysts expect that Guardant Health, Inc. will post -3.49 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Kumud Kalia acquired 2,187 shares of Guardant Health stock in a transaction that occurred on Monday, March 18th. The stock was bought at an average price of $17.82 per share, with a total value of $38,972.34. Following the completion of the purchase, the insider now owns 12,722 shares in the company, valued at $226,706.04. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.20% of the company's stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.